South_agency/E+ via Getty Images
- Zymeworks (ZYME) announced positive Phase 3 HERIZON-GEA-01 trial results for Ziihera (zanidatamab-hrii) as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA), presented at ASCO GI.
- Up to $440.0 million in milestone payments are eligible to be earned related to regulatory approvals
